Notwithstanding, use of JAK-STAT inhibitors in asthma co-existing with obesity should be approached with caution since activation of specific JAK-STAT family members can attenuate the severity of obesity-induced sequelae, including atherosclerosis and hepatic steatosis [146, 147]. Here, SOAT1 is linked to asthma.